Seattle Genetics Inc. (SGEN) Reports Smaller-Than-Expected Loss
More News related to SGEN
- Seattle Genetics Initiates Phase I Clinical Trial of Antibody-Drug Conjugate SGN-75
- Seattle Genetics to Present at Upcoming Investor Conferences
- Seattle Genetics Inc. (SGEN) Reports Smaller-Than-Expected Loss
- Seattle Genetics Highlights Pipeline Progress and Reports Third Quarter 2009 Financial Results
- Leerink Swann Initiates Coverage on Seattle Genetics (SGEN) with a Market Perform; Good Company W/ Solid Prospects
Seattle Genetics Inc. (Nasdaq: SGEN) reports Q3 loss of $0.21, 4 cents better than the analyst estimate of $0.25. Revenue for the quarter was $11.6 million, which compares to the estimate of $9.3 million.
Related Categories
EarningsStocks Mentioned
-0.04Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
